Original articlePPAR-γ agonist Pioglitazone (cas 111025-46-8) reduces microglial proliferation and NF-κB activation in the substantia nigra in the 6-hydroxydopamine model of Parkinson’s disease

Add time:08/29/2019    Source:sciencedirect.com

BackgroundPeroxisome proliferator-activated receptor γ (PPAR-γ) agonists have received much attention in research because of their neuroprotective and anti-inflammatory effects that reduce cell death and halt the progression of neurodegeneration. Thus, this study observed the Pioglitazone (cas 111025-46-8) effects on the main inflammatory markers after 6-hydroxydopamine (6-OHDA) lesion.

We also recommend Trading Suppliers and Manufacturers of Pioglitazone (cas 111025-46-8). Pls Click Website Link as below: cas 111025-46-8 suppliers

Prev:Original ArticleNanoemulsion strategy of Pioglitazone (cas 111025-46-8) for the treatment of skin inflammatory diseases
Next:Original ArticlePreparation of polymer microspheres capable for Pioglitazone (cas 111025-46-8) release to modify macrophages function)